Cyberonics

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Cyberonics sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).

15 total trials none currently recruiting 14 completed later-stage tilt top decile by trial count

Cyberonics: 15 sponsored US clinical trials, none currently recruiting.

Cyberonics sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Epilepsy, with 1 trials.

Top-decile sponsor footprint

Cyberonics ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 73/100

14 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

15 total, page 1 of 1

COMPLETED

Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation

NCT02385526
COMPLETED NA

VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)

NCT01846741
COMPLETED NA

Study to Evaluate a New Device Designed to Collect Heart Activity and Body Movement Data

NCT01626599
COMPLETED NA

3-Dimensional Accelerometer Sub-Study

NCT01612689
COMPLETED

ECG Vector Determination

NCT01486056
COMPLETED

Physiological and Biomechanical Data Collection Study in Epilepsy Subjects

NCT01485016
COMPLETED

Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated

NCT01281293
COMPLETED

Heartbeat Sensitivity Calibration Using the ECG Accessory

NCT01268007
COMPLETED

Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy

NCT01214707
COMPLETED

Heart Rate Changes During Normal Activity, Exercise, and Sleep in Normal Healthy Subjects With and Without Epilepsy

NCT01202682
COMPLETED

Heart Rate Changes in Subjects With Epilepsy

NCT01202669
COMPLETED Phase 4

Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses

NCT00305565
COMPLETED

Treatment-Resistant Depression Registry

NCT00320372
TERMINATED Phase 4

Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures

NCT00215215
COMPLETED NA

Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)

NCT00533832

Phase Distribution

PhaseTrial count
Phase 4 2

Therapeutic Areas

Epilepsy 1

How the Cyberonics archive is shaped

15 indexed studies, none listed as recruiting (0% open); 14 completed (93%).

Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Epilepsy (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Cyberonics: archived-pipeline peers nationwide

Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Cyberonics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%10%20%30%40% Total trials Recruiting share CyberonicsAllakosArbor Research Collaborative for HealthArena PharmaceuticalsArrowhead Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Cyberonics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cyberonics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 15 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cyberonics page

15 registered trials is a research-attention snapshot, not an endorsement of Cyberonics or any single study.

  • None of Cyberonics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Epilepsy is the condition Cyberonics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epilepsy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cyberonics pipeline card: 15 registered trials from official public datasets.Report a data error.